Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omipalisib - GlaxoSmithKline

Drug Profile

Omipalisib - GlaxoSmithKline

Alternative Names: 2126458; GSK-212; GSK-2126458; GSK-458

Latest Information Update: 09 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK
  • Class Antineoplastics; Benzene derivatives; Fluorobenzenes; Pyridazines; Pyridines; Quinolines; Small molecules; Sulfonamides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • No development reported Idiopathic pulmonary fibrosis; Lymphoma; Solid tumours

Most Recent Events

  • 09 Jun 2022 Pharmacodynamics data from a cell line study in acute myeloid lukaemia presented at the 27th Congress of the European Haematology Association (EHA-2022)
  • 11 Dec 2021 Preclinical trials in Acute myeloid leukaemia in United Kingdom (PO)
  • 11 Dec 2021 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top